Description: Cycloclenbuterol  Hydrochloride is 5-(4-Amino-3,5-dichlorophenyl)-3- tert-butyloxazole hydrochloride, is a sympathomimeticamine used by sufferers of breathing disorders as a decongestant and bronchodilator. People with chronic breathing disorders such as asthma use this as a bronchodilator to make breathing easier.

Pharmacological effects: Cycloclenbuterol  Hydrochloride is a β2 agonist with some structural and pharmacological similarities to epinephrine and salbutamol, but its effects are more potent and longer-lasting as a stimulant and thermogenic drug. It causes an increase in aerobic capacity, central nervous system stimulation, blood pressure, and oxygen transportation. It increases the rate at which body fat is metabolized while increasing the body's basal metabolic rate (BMR). It is commonly used for smooth muscle-relaxant properties as a bronchodilator.


Indications: For prolonged treatment of bronchospastic syndrome in mild and moderate atopic and non-atopic bronchial asthma; strain-induced bronchospasm; in the complex therapy of chronic spastic bronchitis and COPD.

Precautions: In concomitant administration with antidiabetics, their dose should be increased due to glycogenolysis stimulation by Cycloclenbuterol. Co-administration with cardiac glycosides, MAO-inhibitors and theophylline may cause heart rhythm disorders. The effect of Cycloclenbuterol is potentiated by tricyclic antidepressants, some antihistamines and levothyroxin and reduced by some antihypertensive products (guanethidine). Halothane and other halogenated hydrocarbon anesthetics and cyclopropane sensitize myocardium and may potentiate the arrhythmogenic effect of β2- sympathomimetics.

Adverse reaction: Insomnia, headache, hyperkinesias, psychic disorders, reddening, sweating, tremor and anxiety, excitability, dizziness; the patients with Parkinson’s syndrome may feel increase of tremor and muscle rigidity; palpitations, tachycardia, reduction or, rarely, rise of blood pressure; urine retention; paradoxical bronchospasm which requires immediate discontinuation of therapy. In patients with diabetes mellitus, hyperglycaemia may develop. The manifestation of such adverse reactions requires dose reduction without need of therapy termination, because they fade within 1-2 weeks after therapy initiation. In prolonged administration, tachyphyllaxis to Cycloclenbuterol may be observed, but sensitivity is restored after discontinuation of therapy